-
- Work to restore the original intent and benefit of the 340B program for vulnerable and at-risk patients
-
- Facilitate conversations and awareness around practices such as value-based pricing, which bases the cost of prescription drugs on outcomes delivered. www.americanprogress.org/article/value-based-pricing-prescription-drugs-benefits-patients-promotes-innovation/
-
- Highlight emerging practices such as Pfizer’s recently enacted pledge to refund patients if its new lung cancer drug does not perform as intended. https://www.statnews.com/pharmalot/2021/10/13/pfizer-lung-cancer-warranty-medicare/